Atara Biotherapeutics Inc
NASDAQ:ATRA
ROA
Return on Assets
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
ROA Across Competitors
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| US |
|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
59m USD |
-14%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-391%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
337.5B USD |
3%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
158.7B USD |
7%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
136.9B USD |
11%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117B USD |
-4%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-67%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.1B AUD |
7%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
57.3B USD |
13%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-21%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.1B USD |
-7%
|
Atara Biotherapeutics Inc
Glance View
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in South San Francisco, California and currently employs 578 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.
See Also
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
Based on Atara Biotherapeutics Inc's most recent financial statements, the company has ROA of -13.8%.
You don't have any saved screeners yet